comprehensive -WSS

comprehensive

author：explore 2025-10-01 23:31:10 - browse：5362

Patient treated with Impella in the heart. -- health tech coverage from STAT — Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. Business Wire

The Food and Drug Administration is following through on its promise to regulate more health software tools, starting with a public reprimand of Johnson & Johnson’s heart pump company, Abiomed.

Abiomed, which was bought by Johnson & Johnson late last year for $16.6 billion, sells devices for heart failure patients as well as patient monitoring software. The FDA published a warning letter on Wednesday telling the company it should have submitted its software for approval before putting it on the market. The agency also took issue with Abiomed’s failure to report various problems with its heart pumps.

The letter comes a year after the Food and Drug Administration announced its intention to regulate more health software tools, sending the industry into an uproar.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Moonlake's readout produced a cash windfall. Risks remain

WSS

Hollywood unions extend contract negotiations for actors

Data don't support strong claims for Covid

Sutter Health’s antitrust win overturned by appeals court

Take antibiotics after sex, CDC recommends for certain risk groups

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

United colonoscopy coverage change 'may cost lives,' doctors say

explore

comprehensive

knowledge

Peter Hotez and the public health issue of online harassment

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Tori Bowie and the unacceptable rates of Black maternal death

FTC loses bid to block Novant's North Carolina hospital merger

In Memoriam: Notable people who died in 2023

CMS got Medicare Advantage quality rating wrong, judge rules

The cancer drug shortage isn’t new — and neither are the solutions

Elevance PBM president out as customers face prescription chaos

In age of alternative facts, a scholarly course on calling out crap

Continuity nursing helped my family in our darkest PICU moments

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

The cancer drug shortage isn’t new — and neither are the solutions

Medical records are filled with copy

Eli Lilly’s Zepbound improved liver scarring in mid

ASCO Daily Recap: CAR

United colonoscopy coverage change 'may cost lives,' doctors say

focus

hotspot

focus

Wikipedia